The Food and Drug Administration officially approved a drug called flibanserin designed to treat women with hypoactive sexual desire disorder. The drug will be manufactured by Sprout Pharmaceuticals and will officially be sold under the name ‘Addyi.’

Politico reports:

But the agency’s decision... comes with a requirement that the company take steps to ensure doctors prescribe flibanserin carefully and make women aware of its health risks. The drug will only be available through certified health care professionals and certified pharmacies. It will come with a black boxed warning to highlight the risk of severe blood pressure drops and fainting in patients who drink alcohol or use certain other drugs during treatment.

The FDA has also requested three more studies focused on the interaction between the drug and alcohol consumption. The drug was up for approval two times before (first in 2010), but it was rejected both times.

Advertisement

Flibanserin works by gradually increasing the amount of neurotransmitters noradrenaline and dopamine into the cerebral cortex — essentially bumping up the motivation factor and making the prospect of sex more exciting.

“Today’s approval provides women distressed by their low sexual desire with an approved treatment option,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction.”


Contact the author at joanna.rothkopf@jezebel.com.

Image via AP.

Click here to view this kinja-labs.com embed.